{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Gallbladder+Carcinoma&page=4",
    "query": {
      "condition": "Metastatic Gallbladder Carcinoma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 86,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Gallbladder+Carcinoma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Gallbladder+Carcinoma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T04:56:39.665Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02053376",
      "title": "A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Biliary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nathan Bahary, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2014-01",
      "completion_date": "2018-05-14",
      "has_results": true,
      "last_update_posted_date": "2019-01-30",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02053376"
    },
    {
      "nct_id": "NCT00003046",
      "title": "Interleukin-12 in Treating Patients With Cancer in the Abdomen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anal Cancer",
        "Colorectal Cancer",
        "Gallbladder Cancer",
        "Gastric Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Recombinant Interleukin-12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "1997-08",
      "completion_date": "2001-10",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003046"
    },
    {
      "nct_id": "NCT05506943",
      "title": "A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Biliary Tract Cancer",
        "Cholangiocarcinoma",
        "Gall Bladder Cancer",
        "Ampullary Cancer"
      ],
      "interventions": [
        {
          "name": "CTX-009",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Compass Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2023-01-09",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05506943"
    },
    {
      "nct_id": "NCT00386516",
      "title": "Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer of the Bile Duct",
        "Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "GM-CT-01",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galectin Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2006-09",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00386516"
    },
    {
      "nct_id": "NCT00059865",
      "title": "Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Liver Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed disodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2004-01",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2016-12-07",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 41,
      "location_summary": "Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 29 more",
      "locations": [
        {
          "city": "Chanute",
          "state": "Kansas"
        },
        {
          "city": "Dodge City",
          "state": "Kansas"
        },
        {
          "city": "El Dorado",
          "state": "Kansas"
        },
        {
          "city": "Kingman",
          "state": "Kansas"
        },
        {
          "city": "Liberal",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00059865"
    },
    {
      "nct_id": "NCT01093222",
      "title": "Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extrahepatic Bile Duct Adenocarcinoma",
        "Gallbladder Adenocarcinoma",
        "Gallbladder Adenocarcinoma With Squamous Metaplasia",
        "Hilar Cholangiocarcinoma",
        "Recurrent Extrahepatic Bile Duct Carcinoma",
        "Recurrent Gallbladder Carcinoma",
        "Undifferentiated Gallbladder Carcinoma",
        "Unresectable Extrahepatic Bile Duct Carcinoma",
        "Unresectable Gallbladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Erlotinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2010-04",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-06-30",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 141,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 95 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Marysville",
          "state": "California"
        },
        {
          "city": "Novato",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01093222"
    },
    {
      "nct_id": "NCT00004604",
      "title": "Biological Therapy in Treating Patients With Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Liver Cancer",
        "Lung Cancer",
        "Metastatic Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "CEA RNA-pulsed DC cancer vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "1997-02",
      "completion_date": "2002-07",
      "has_results": false,
      "last_update_posted_date": "2013-02-22",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004604"
    },
    {
      "nct_id": "NCT02520141",
      "title": "Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholangiocarcinoma",
        "Liver and Intrahepatic Bile Duct Carcinoma",
        "Stage III Gallbladder Cancer AJCC v7",
        "Stage III Intrahepatic Cholangiocarcinoma AJCC v7",
        "Stage IIIA Gallbladder Cancer AJCC v7",
        "Stage IIIB Gallbladder Cancer AJCC v7",
        "Stage IV Gallbladder Cancer AJCC v7",
        "Stage IVA Gallbladder Cancer AJCC v7",
        "Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7",
        "Stage IVB Gallbladder Cancer AJCC v7",
        "Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7",
        "Unresectable Gallbladder Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2015-12-29",
      "completion_date": "2022-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02520141"
    },
    {
      "nct_id": "NCT07793253",
      "title": "Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Biliary Tract Cancers",
        "Intrahepatic Cholangiocarcinoma (Icc)",
        "Extrahepatic Cholangiocarcinoma",
        "Gallbladder Carcinoma",
        "Ampulla of Vater Carcinoma",
        "Ampullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "Daraxonrasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2026-11",
      "completion_date": "2030-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07793253"
    },
    {
      "nct_id": "NCT00003867",
      "title": "Irinotecan and Capecitabine in Treating Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 30,
      "start_date": "1999-03",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2018-09-10",
      "last_synced_at": "2026-10-17T04:56:39.665Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003867"
    }
  ]
}